Merck announced topline data from 2 ongoing pivotal phase 3 trials (COUGH-1 and COUGH-2) for gefapixant (MK-7264) for the treatment of refractory or unexplained chronic cough. Merck announced topline ...

(RTTNews) - Merck & Co. Inc. (MRK) on Tuesday announced the results from two pivotal Phase 3 trials, COUGH-1 and COUGH-2, evaluating the efficacy and safety of gefapixant (MK-7264) for the potential ...

Credit: Getty Images. Researchers conducted pooled analysis of the COUGH-1 and COUGH-2 phase 3 trials of gefapixant for treating refractory/unexplained chronic cough. In phase 3 randomized clinical ...

Please provide your email address to receive an email when new articles are posted on . Gefapixant 45 mg twice daily resulted in clinically important reductions in cough frequency compared with ...

Cough is the most common chief complaint in the United States and Australia. 1 Although the differential diagnosis of cough in children is extensive, coughs can have very characteristic presentations ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced the results from two pivotal Phase 3 trials (COUGH-1 and COUGH-2) evaluating the ...

Please provide your email address to receive an email when new articles are posted on . Treatment with gefapixant, a P2X3 receptor antagonist reduced cough frequency and cough-related quality of life ...

Physicians may be able to better identify patients with chronic cough using the combination of 2 coughing tests. Researchers found the combination of the cough suppression test and the cough challenge ...

MANCHESTER, England & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Axalbion, a clinical-stage biopharmaceutical company focused on developing novel medicines to treat cough, today announced positive ...